Document is current
Any future updates will be listed below
-
Authors
Petrovic, Dusan
Bodinier, Barbara
Dagnino, Sonia
Whitaker, Matthew
Karimi, Maryam
Campanella, Gianluca
Haugdahl Nøst, Therese
Polidoro, Silvia
Palli, Domenico
Krogh, Vittorio
Tumino, Rosario
Sacerdote, Carlotta
Panico, Salvatore
Lund, Eiliv
Dugué, Pierre-Antoine
Giles, Graham G.
Severi, Gianluca
Southey, Melissa
Vineis, Paolo
Stringhini, Silvia
Bochud, Murielle
Sandanger, Torkjel M.
Vermeulen, Roel C. H.
Guida, Florence
Chadeau-Hyam, Marc https://orcid.org/0000-0001-8341-5436
-
Funding
Funding for this research was provided by:
Cancer Research UK (22184)
European Research Council (ERC-2008-AdG-232997)
FRIPRO (FRIPRO 262111)
Horizon 2020 Framework Programme (874627)
H2020 Marie Skłodowska-Curie Actions (708392)
National Foundation for Science and Technology Development (SNSF DocMobility grant P1LAP3_178061)
- License Information
-
More Information
Article History
Received: 28 September 2021
Accepted: 25 April 2022
First Online: 20 May 2022
Declarations
:
: MC-H holds shares in the O-SMOSE company and has no conflict of interest to disclose. Consulting activities conducted by the company are independent of the present work. The authors have no conflict of interest to disclose. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.
: All study participants gave written informed consent for the study. For EPIC Italy, the research was approved by the Ethics Committees at the Italian Institute of Genomic Medicine (IIGM, Turin, Italy). For NOWAC, the study was approved by the Regional Committee for Medical and Health Research Ethics in North Norway.
